#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Leukocyte adhesion deficiency type I Fms-like tyrosine kinase 3 positive Polycystic liver disease Hyperadrenocorticism Desmoplastic small round cell tumour Kidney transplant rejection Oesophageal adenocarcinoma Antithrombin III deficiency Emphysema Myxofibrosarcoma Anal squamous cell carcinoma B-cell small lymphocytic lymphoma refractory Mucous membrane pemphigoid Small for dates baby Congenital aplastic anaemia More trials…

    Learn about Rare Diseases

    Synovial sarcoma metastatic – Basic Information Idiopathic inflammatory myopathy – Life with Disease Extranodal marginal zone B-cell lymphoma (MALT type) – Basic Information MELAS syndrome Mucopolysaccharidosis III – Diagnostics Methylmalonic acidaemia – Life with Disease Lennox-Gastaut syndrome Congenital hypotransferrinaemia – Diagnostics Pemphigoid – Trials in Disease Focal segmental glomerulosclerosis – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Leuprorelin Coffee Charcoal Mk-1200 Xp-Dc+Tl+Klh Ranibizumab Incb099280 Carbasalate Calcium Avelumab Calcitriol Lbl-007 Flortaucipir (18F) BI 456906 Siremadlin Pyridoxine [89Zr]Bms-986279 For-6219 [18F]Fluoro-Peg-Folate Benralizumab Zelicapavir Cefixime Trihydrate More therapies…

    Learn about Your Condition

    Ocular lymphoma Aicardi-Goutieres syndrome Embolism Retinopathy proliferative Haematological malignancy Chronic lymphocytic leukaemia Iron overload Peyronie's disease Lymphoedema Hepatic neoplasm Vulvovaginal candidiasis Periodontitis Mitochondrial DNA depletion Haemoptysis Erythema migrans More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Jean Perrin

Centre Jean Perrin

58 Rue Montalembert, Clermont Ferrand, 63000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Amiloride tablets for prevention of migraine with aura attacks

    Recruiting

    4 1 1
    Investigated Diseases:
    • Migraine with aura
    Investigated Drugs:
    • Amiloride Hydrochloride Dihydrate
    France

  • Safety and efficacy of obinutuzumab in patients with active diffuse systemic sclerosis: a randomized, double-blind, placebo-controlled trial

    Not yet recruiting

    2 1 1
    Investigated Diseases:
    • Systemic scleroderma
    Investigated Drugs:
    • Obinutuzumab
    France

  • Evaluation of Cefazolin versus Placebo for Preventing Surgical Site Infection in Breast Cancer Lumpectomy Patients

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Breast cancer
    Investigated Drugs:
    • Sodium Chloride Ph. Eur.
    • Sodium Hydrogen Carbonate Pheur
    • Cefazolin Sodium
    France

  • Study of Camizestrant and Abemaciclib in Patients with ER‑positive HER2‑negative Metastatic Breast Cancer Who Show Rising ctDNA

    Not yet recruiting

    3 1 1 1
    Investigated Drugs:
    • Abemaciclib
    • Camizestrant
    France

  • Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Enfortumab Vedotin
    • Pembrolizumab
    France Germany Italy Poland Spain

  • A study to evaluate the safety and effectiveness of nivolumab and imiquimod in adults with vulvar squamous cell carcinoma

    Not yet recruiting

    1 1 1 1
    Investigated Drugs:
    • Imiquimod
    • Nivolumab
    France

  • Study evaluating the omission of exemestane, letrozole, anastrozole, and tamoxifen in postmenopausal women with low-risk early breast cancer.

    Not yet recruiting

    2 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Anastrozole
    • Exemestane
    • Letrozole
    France

  • Study Comparing Different Antibiotic Treatments for ICU Patients with Hospital-Acquired Sepsis: Focus on Cefepime and Drug Combination

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Sepsis
    Investigated Drugs:
    • Amikacin
    • Cefepime
    • Piperacillin
    France

  • Study on the Use of 64Cu-PSMA I&T to Detect Lymph Node Spread in Men with Newly Diagnosed Prostate Cancer Before Surgery

    Not yet recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • 64CU-PSMA I&T
    France Italy Spain

  • Study of Atezolizumab with BCG Treatment for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Previously Received BCG

    Not yet recruiting

    3 1 1 1
    Investigated Diseases:
    • Bladder cancer
    Investigated Drugs:
    • Atezolizumab
    Belgium France Spain
Previous Page
1 … 8 9 10 11 12 … 20
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!